bibliography - shodhgangashodhganga.inflibnet.ac.in/bitstream/10603/33897/1/bibliography.pdf ·...
TRANSCRIPT
Bibliography Aapro, M.S. 2001. Adjuvant therapy of primary breast cancer: a review of key findings from the
7th international conference, St. Gallen. Oncologist., 6, 376–385.
Agarwal, C. Tyagi, A. Agarwal, R. 2006. Gallic acid causes inactivating phosphorylation of
cdc25A/cdc25C-cdc2 via ATM-Chk2 activation, leading to cell cycle arrest, and induces
apoptosis in human prostate carcinoma DU145 cells. Mol Cancer Ther., 5: 3294-302.
Ahmad, A. Mukherhjee, P. Senapati, S. Mandal, D. Khan, M.I. Kumar, R. Sastry, M. 2003.
Extracellular biosynthesis of silver nanoparticles using the fungus Fusarium oxysporum.
Colloids Surf. B., 28: 313-318.
Akita, H. Kudo, A. Minoura, A. Yamaguti, M. Khalil, I.A. Moriguchi, R. 2009. Multi-layered
nanoparticles for penetrating the endosome and nuclear membrane via a step-wise
membrane fusion process. Biomaterials., 30: 2940–2949.
Alexis, F. Pridgen, E. Molnar, L.K. Farokhzad, O.C. 2008. Factors affecting the clearance and
biodistribution of polymeric nanoparticles. Mol. Pharmacol., 5 (4) : 505–515.
Altieri, D.C. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer., 3: 46-
54.
Altieri, D.C. 2008. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev
Cancer., 81: 61–70.
Ambrosini, H. Matsuzawa, C. Altieri, D.C. 1997. A novel anti-apoptotic gene, survivin
expressed in cancer and luymphoma. Nat Med., 3: 917-21.
Angell. 2008. A study in to the potential role of survivin localization in resistance to drug-
induced apoptosis. Bioscience Horizons., 1: 2
AshaRani, P.V. Low Kah Mun, G. Hande, M.P. 2009. Valiyaveettil S. Cytotoxicity and
genotoxicity of silver nanoparticles in human cells. ACS Nano., 3: 279-290.
Bibliography Assaraf, Y.G. 2007. Molecular basis of antifolate resistance. Cancer Metast. Rev., 26: 153–181.
Banerjee, R. Tyagi, P. Li, S. Huang, L. 2004. Anisamide-targeted stealth liposomes: a
potent carrier for targeting doxorubicin to human prostate cancer cells. Int. J. Cancer.,
112: 693–700.
Atobe, K. Ishida, T. Ishida, E. Hashimoto, K. Kobayashi, H. Yasuda, J. Aoki, T. Obata, K.
Kikuchi, H. Akita, H. Asai, T. Harashima, H. Oku, N. Kiwada, H. 2007. In vitro
efficacy of a sterically stabilized immunoliposomes targeted to membrane type1 matrix
metalloproteinase (MT1-MMP). Biol. Pharm. Bull., 30 (5): 972-978.
Avgoustakis, K. 2002. PLGA–mPEG nanoparticles of cisplatin: in vitro nanoparticle
degradation, in vitro drug release and in vivo drug residence in blood properties. J
Control Release., 791 : 23–35.
Baracca, A. Sgarbi, G. Solaini, G. Lenaz, G. 2003. Rhodamine 123 as a probe of mitochondrial
membrane potential: evaluation of proton flux through F0 during ATP synthesis.
Biochim Biophys Acta.,1606: 137–146.
Bareford, L.M. Swaan, P.W. 2007. Endocytic mechanisms for targeted drug delivery. Adv. Drug.
Deliv. Rev., 59: 748–758.
Barnhart, B.C. Alappat, E.C. Peter, M.E. 2003. The CD95 type I/type II model. Seminors in
Immunology ., 15: 185–193.
Basu, S. Chaudhuri, P. Sengupta, S. 2009. Targeting oncogenic signaling pathways by exploiting
nanotechnology. Cell Cycle., 8: 3480–3487.
Basu, S. Harfouche, R. Soni, S. Chimote, G. Mashelkar, R.A. Sengupta, S. 2009. Nanoparticle-
mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc. Natl
Acad. Sci., 106: 7957-7961.
Bibliography Bhattacharya, R. Mukherjee, P. 2008. Biological properties of “naked” metal nanoparticles.
Advanced Drug Delivery Reviews., 60 : 1289-01306.
Boatright, K.M. Salvesen, G.S. 2003. Mechanisms of caspase activation. Current Opinion in
Cell Biology ., 15: 725–731.
Bodnar, M. Hartmann, J.F. Borbely, J. 2005. Preparation and characterization of chitosan-
based nanoparticles. Biomacromolecules., 6 : 2521–2527.
Bold, R.J. Termuhlen, P.M. McConkey, D.J. 1997. Apoptosis cancer and cancer therapy. Surg
Oncol., 6: 133-142.
Bonneterre, J. Thurlimann, B. Robertson, J.F.R. Krzakowski, M. Mauriac, L. Koralewski, P.
2000. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in
668 postmenopausal women: results of the tamoxifen or arimidex randomized group
efficacy and tolerability study. J Clin Oncol., 18: 3748–3757.
Brid, M. Ryan, Norma O’Donovan. Michael J Duffy. 2009. Survivin: A new target for anti-
cancer therapy. Cancer treatment Review., 12: 84-96.
Brown, S.D. Nativo, P. Smith, J.A. Stirling, D. 2010. Gold nanoparticles for the improved
anticancer drug delivery of the active component of oxaliplatin. J. Am. Chem. Soc., 132:
4678–4684.
Broxterman, H.J. Gotink, K.J. Verheul, H.M. 2009. Understanding the causes of multidrug
resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist. Update.,
12: 114–126.
Bulut, E. Rapid Ozacar, M. 2009. Facile synthesis of silver nanostructure using hydrolyz-able
tannin. Ind Eng Chem Res., 48: 5686-5690.
Bibliography Burz, C. Berinda n-Neagoe, I. Balaces cu, O. Irimie, A. 2009. Apoptosis in cancer: key
molecular signaling pathways and therapy targets. Acta Oncol., 488: 11-21.
Callegari, A. Tonti, D. Chergui, M. 2003. Photochemically grown silver nanoparticles with
wavelength-controlled size and shape. Nano Lett., 3: 1565-1568.
Cameron, D.A. Ritchie, A.A. Langdon, S. Anderson, T.J. Miller, W.R. 1997. Tamoxifen induced
apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer
Res Treat., 45: 99–107.
Carey, L.A. Dees, E.C. Sawyer, L. Gatti, L. Moore, D.T. Collichio, F. 2007. The triple negative
paradox: primary tumor chemo-sensitivity of breast cancer subtypes. Clin. Cancer Res.,
13: 2329–2334.
Cascone, M.G. 2002. Poly(vinyl alcohol) hydrogels as hydrophilic matrices for the release of
lipophilic drugs loaded in PLGA nanoparticles. J. Mat. Sci. Mat., Med.13: 29–32.
Castedo, M. Perfettini, J. L. Roumier, T. Andreau, K. and Kroemer, G. 2004. Cell death by
mitotic catastrophe: A molecular definition. Oncogene., 23: 2825-2837.
Chan, J. 2000. Down- regulation of survivin by antisense oligonucleotides increase apoptosis,
inhibits cytokinesis and anchorage independent growth. Neoplasia., 2: 235-241.
Chau, C.F. Wu, S.H. Yen, G.C. 2007. The development of regulations for food nanotechnology.
Trends Food Sci Tech., 18: 269-280.
Chen, A.M. Zhang, M. Wei, D.G. Stueber, D. Taratula, O. Minko, T. He, H.X. 2009. Co-
delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances
the efficacy of chemotherapy in multidrug-resistant cancer cells. Small., 5: 2673–2677.
Chen, X. Schluesener, H.J.2008. Nanosilver: a nanoproduct in medical application. Toxicol Lett.,
176: 1-12.
Bibliography Cho, K.J. Wang, X. Nie, S.M. Chen, Z. Shin, D.M. 2008. Therapeutic nanoparticles for drug
delivery in cancer. Clin. Cancer. Res., 14: 1310–1316.
Choedon, T. Shukla, S.K. Kumar, V. 2010. Chemopreventive and anti-cancer properties of the
aqueous extract of flowers of Butea monosperma. J Ethnopharmacol., 129: 208-213.
Circu, M.L. Aw, T.Y. 2010. Reactive oxygen species, cellular redox systems, and apoptosis.
Free Radic. Biol.Med., 48: 749-762.
Cleator, S. Heller, W. Coombes, R.C. 2007. Triple-negative breast cancer: therapeutic options.
Lancet Oncol., 8: 235-244.
Cobleigh, M.A. Vogel, C.L. Tripathy, D. Robert, N.J. Scholl, S. Fehrenbacher. L. 1999.
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal
antibody in women who have HER2-overexpressing metastatic breast cancer that has
progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639–2648.
Colnaghi, R. Connel, C.M . Barrett, R.M .2006. Sepaerating the anti-apoptotic and mitotic roles
of survivin. J.Biol.Chem., 281: 33450-33456.
Conlin, A.K. Seidman, A.D. Bach, A., et al., 2010. Phase II trial of weekly nanoparticle albumin-
bound paclitaxel with carboplatin and trastuzumab as first-line therapy forwomen with
HER2-overexpressing metastatic breast cancer. Clin. Breast Cancer .,10: 281–287.
Conway, E.M. Zwerts, F. Van Eygen, V. 2003. Survivin-dependent angiogenesis in ischemic
brain: molecular mechanisms of hypoxia-induced up-regulation. Am J Pathol., 1633:
935–946.
Couvreur, P. Vauthier, C. 2006. Nanotechnology: intelligent design to treat complex disease.
Pharm. Res., 23: 1417-1450.
Bibliography Culy, C.R. Clemett, D. Wiseman, L.R. 2000. Oxaliplatin: A review of its pharmacological
properties and clinical efficacy in metastatic colorectal cancer and its potential in other
malignancies. Drugs., 60 : 895-924.
Cuzick, J. Powles, T. Veronesi, U. Forbes, J. Edwards, R. Ashley, S. 2003. Overview of the
main outcomes in breast-cancer prevention trials. Lancet., 361: 296–300.
Dai, Y. Grant, S. 2007. Targeting multiple arms of the apoptotic regulatory machinery. Cancer
Res., 67: 2908–2911.
Debatin, K.M., 2004. Apoptosis pathways in cancer and cancer therapy. Cancer Immunology
Immunotheraphy., 53: 153–159.
Decuzzi, P. Ferrari, M. 2006. The adhesive strength of non-spherical particles mediated by
specific interactions. Biomaterials., 27 : 5307–5314.
Decuzzi, P. Lee, S. Bhushan, B. Ferrari, M. 2005. A theoretical model for the margination of
particles within blood vessels. Ann. Biomed. Eng., 33: 179–190.
Decuzzi, P. Ferrari, M. 2008. Design maps for nanoparticles targeting the diseased
microvasculature . Biomaterials., 29 : 377–384.
Di, A and Paolo. 2004. Liposomal anticancer therapy: pharmacokinetic and clinical aspects. J.
Chemother., 16: 90–93.
Dimitrijevic, N.M. Bartels, D.M. Jonah, C.D. Takahashi, K. Rajh, T. 2001. Radiolytically
induced formation and optical absorption spectra of colloidal silver nanoparticles in
supercritical ethane. J Phys Chem B., 105: 954-959.
Dubas, S.T. Pimpan, V. 2008. Humic acid assisted synthesis of silver nanoparticles and its
application to herbicide detection. Mater Lett., 62: 2661-2663.
Bibliography Duffy, M.J. O’Donovan N, Brennan D.J. Gallagher W.M. Ryan, B.M. 2007. Survivin: a
promising tumor biomarker. Cancer Lett., 2491: 49–60.
Earnshaw, W.C. 2005. Cell biology keeping survivin nimble at centromers in mitosis. Science.,
310: 1443-1444.
Endoh, A. Asanuma, K. Moriai, R. Yamada, M. Koyanagi, Y. Sato, T. 2001. Expression of
survivin mRNA in CD4+ cells. Clin. Chim.Acta., 306: 149-151.
Farokhzad, O.C. Karp, J.M. Langer, R. 2006. Nanoparticle-aptamer bio-conjugates for cancer
targeting Expert Opin. Drug Deliv., 3: 311–324.
Fawell, S. Seery, J. Daikh, Y. Moore, C. Chen, L.L. Pepinsky, B. Barsoum, J. 1994. Tat-
mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A., 91:
664–668.
Fendly, B.M. Winget, M. Hudziak, R.M. Lipari, M.T. Napier, M.A. Ullrich, A. 1990.
Characterization of murine monoclonal antibodies reactive to either the human epidermal
growth factor receptor or HER2/neu gene product Cancer. Res., 50: 1550–1558.
Feng, S.S. Mu, L. Win, K.Y. Huang, G. 2004. Nanoparticles of biodegradable polymers for
clinical administration of paclitaxel. Curr. Med. Chem., 11: 413.
Fengzhi Li and Xiang Ling .2006. Survivin study: An update of “What is the Next Wave”.
J.Cell. Physio., 208: 476-86.
Ferrari, M. 2005. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer., 5:
161–171.
Ferrari, M. 2005. Nanovector therapeutics. Curr. Opin. Chem. Biol., 9: 343-346.
Ferrari, M. 2008. Beyond drug delivery. Nat. Nanotechnol., 3; 131–132.
Bibliography Fesik, S.W. 2005. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer.,
511: 876–85.
Fessi, H. Puisieux, F. Ph. Devissaguet, J. Ammoury, N. Benita, S. 1989. Nanocapsule formation
by interfacial polymer deposition following solvent displacement. Int. J. Pharm., 55
(1):1–4.
Fisher, B. Costantino, J.P. Wickerham, D.L. Cecchini, R.S. Cronin, W.M. Robidoux, A. 2005.
Tamoxifen for the prevention of breast cancer: current status of the National Surgical
Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst., 97: 1652–1662.
Fornari, F.A. Randolph, J.K. Yalowich, J.C. Ritke, M.K. Gewirtz, D.A. Interference by
doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. Pharmacol., 45:
649–656 (1994).
Fujie, Y. Yamamoto, H. Ngan, C.Y. Takagi, A. Hayashi, T. Suzuki, R. Ezumi, K. Takemasa,
I. Ikeda, M. Sekimoto, M. Matsuura, N. Monden, M. 2005. Oxaliplatin, a Potent
Inhibitor of Survivin, Enhances Paclitaxel-induced Apoptosis and Mitotic Catastrophe in
Colon Cancer Cells. Jpn J Clin Oncol., 35: 453-463.
Fujie, Y. Hirofumi Yamamoto, Chew Yee Ngan, Akimitsu Takagi, Taro Hayashi, Rei Suzuki,
Koji Ezumi, Ichiro Takemasa, Masataka Ikeda, Mitsugu Sekimoto, Nariaki Matsuura and
Morito Monden. 2005. Oxaliplatin, a Potent Inhibitor of Survivin, Enhances Paclitaxel-
induced Apoptosis and Mitotic Catastrophe in Colon Cancer Cells. Jpn J Clin Oncol
.,35(8)4: 53–463.
Gabizon, A. Shmeeda, H. Horowitz, A.T. Zalipsky, S. 2004. Tumor cell targeting of liposome-
entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv.Drug Deliv.
Rev., 56:1177-1192.
Bibliography Garrec , L.D. Gori, S. Luo, L. Lessard, D. Smith, D.C. Yessine, M.A. Ranger, M. Leroux,
J.C. 2004. Poly (N-vinylpyrrolidone)-block-poly(D, L-lactide) as a new polymeric
solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J. Control.
Release., 99 (1) : 83–101.
Gentile, F. Ferrari, M. Decuzzi, P. 2008. The transport of nanoparticles in blood vessels: the
effect of vessel permeability and blood rheology. Ann. Biomed. Eng., 36: 254–261.
Ghavami, S. Hashemi, M. Ande, S.R. 2009. Apoptosis and cancer: mutations within caspase
genes. J Med Genet., 46(8): 497–510.
Gibb, R.K. Taylor, D.D. Wan, T. O’Connor, D.M. Doering, D.L. Taylor, C.G. 1997. Apoptosis
as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell
lines. Gynecol Oncol., 65: 13-22.
Giodini, A. Kallio, M.J. Wall, N.R. 2002. Regulation of microtubule stability and mitotic
progression by survivin. Cancer Res., 62: 2462-2467.
Green, D.R. Kroemer, G. 2004. The pathophysiology of mitochondrial cell death. Science., 305:
626-629.
Green, J.J. Chiu, E. Leshchiner, E.S. Shi, J. Langer, R. Anderson, D.G. 2007. Electrostatic
ligand coatings of nanoparticles enable ligand-specific gene delivery to human primary
cells. Nano Lett., 7: 874–879.
Green, S. Walter, P. Kumar, V. Krust, A. Bornert, J.M. Argos, P. 1986. Human oestrogen
receptor cDNA: sequence, expression and homology. Nature., 320: 134-139.
Hanahan, D and Weinberg, R.A. 2011. Hallmarks of Cancer: The Next Generation. Cell., 144:
646-674.
Bibliography Henneke, P. Golenbock, D.T. 2004. Phagocytosis, innate immunity, and host-pathogen
specificity. J. Exp. Med., 199: 1–4.
Henry, S.M. El-Sayed, M.E. Pirie, C.M. Hoffman, A.S. Stayton, P.S. 2006. pH-responsive
poly(styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery.
Biomacromolecules ., 7: 2407–2414.
Hsin, Y.H. Chen, C.F. Huang, S. Shih, T.S, Lai, P.S. Chueh, P.J. 2008. The apoptotic effect of
nanosilver is mediated by a ROS- and JNK-dependent mechanism involving the
mitochondrial pathway in NIH3T3 cells. Toxicol Lett., 179: 130-139.
Hu, C.M. Zhang, L.F. 2009. Therapeutic nanoparticles to combat cancer drug resistance. Curr.
Drug Metab., 10: 836–841.
Hu, R. Yong, K.T. Roy, I. Ding, H. He, S. Prasad, P.N. 2009. Metallic nanostructures as
localized Plasmon resonance enhanced scattering probes for multiplex dark field targeted
imaging of cancer cells. J Phys Chem C: Nanomater Interfaces., 113: 2676-84.
Huang, S.T. Yang, R.C. Lee, P.N. Yang, S.H. Liao, S.K. Chen, T.Y. 2006. Anti-tumor and anti
angiogenic effects of Phyllanthus urinaria in mice bearing Lewis lung carcinoma. Int
Immunopharmacol .,6: 870–879.
Hussain, S. M. Hess, K. L. Gearhart, J. M. Geiss, K. T. and Schlager, J. J. 2005. In vitro toxicity
of nanoparticles in BRL-3A rat liver cells. Toxicol. In Vitro., 19: 975-983.
J.M. Elwood, B. Cox, A.K. Richardson. 1993. The effectiveness of breast cancer screening by
mammography in younger women. J. Curr. Clin. Trials., 32.
Jain, A. Jain, S.K. Ganesh, N. Barve, J. Beg, A.M. 2010. Design and development of ligand-
appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal
cancer. Nanomedicine., 6: 179-190.
Bibliography Jayshree, P.D. Vipin, K. 2008. Annona squamosa L. Phytochemical analysis and Antimicrobial
Screening. J of Phar Res., 1: 34-38.
Jemal, A. Siegel, R. Ward, E. Murray,T. Xu, J. Thun, M J. 2007. Cancer statistics. CA Cancer
J. Clin., 57: 43–66.
Joerger, K.T. Joerger, R. Olsson, E. Granqvist, C.G. 2001. Bacteria as workers in the living
factory: metal-accumulating bacteria and their potential for materials science. Trends
Biotechnol ., 19: 15–20.
Juan, B.H. Zhang, Z.M. Gong, J. 2006. Biological synthesis of semiconductor zinc sulfide
nanoparticles by immobilized Rhodobacter sphaeroides. Biotechnol Lett., 28: 1135–
1139.
Kaitna, S. Mendosa, M. Jantch-Plunger, V. and Glotar, M. 2000. INCENP and Aurora like
kinase form a complex essential for chromosome segregation and efficient completion of
cytokinesis. Curr Biol., 10:1072-1081.
Kalimuthu, K. Babu, R.S. Venkataraman, D. Bilal, M. Gurunathan, S. 2008. Biosynthesis of
silver nanocrystals byBacillus licheniformis. Colloids Surf B., 65: 150–153.
Kam, N.W. O'Connell, M. Wisdom, J.A. Dai, H. 2005. Carbon nanotubes as multifunctional
biological transporters and near-infrared agents for selective cancer cell destruction.
Proc. Natl. Acad. Sci., 102: 11600–11605.
Kamada, H. Tsutsumi, Y. Yamamoto, Y. Kihira, T. Kaneda, Y. Mu, Y. Kodaira, H. Tsunoda, S.
Nakagawa, S. Mayumi, T. 2000. Antitumor activity of tumor necrosis factor-alpha
conjugated with polyvinylpyrrolid one on solid tumors in mice. Cancer Res., 60 (22):
6416– 6420.
Bibliography Kaneda, Y. Tsutsumi, Y. Yoshioka, Y. Kamada, H. Yamamoto, Y. Kodaira ,H. 2004. The use of
PVP as a polymeric carrier to improve the plasma half-life of drugs. Biomaterials., 25:
3259-66.
Karon, M. Weissman, S. Meyer, C. Henry, P. 1965. Studies of DNA, RNA, and Protein
Synthesis in Cultured Human Cells Exposed to 8-Azaguanine. Cancer Res., 25: 185-192.
Kathiresan, K. Manivannan, S. Nabeel, M.A. Dhivya, B. 2009. Studies on silver nanoparticles
synthesized by a marine fungus, Penicillium fellutanum isolated from coastal mangrove
sediment. Colloids Surf B Biointerfaces., 71:133–137.
Kawada, M. Ohno, Y. Ri, Y. Ikoma, T. Yuugetu, H. Asai, T. 2001. Anti-tumor effect of gallic
acid on LL-2 lung cancer cells transplanted in mice. Anticancer Drugs., 12: 847-852.
Kerlikowske, K. 1997. Efficacy of screening mammography among women aged 40 to 49 years
and 50 to 69 years: comparison of relative and absolute benefit. J. Natl. Cancer Inst.
Monogr., 22: 79–86.
Kiemer, A.K. Hartung, T. Huber, C. 2003. Vollmar AM. Phyllanthus amarus has anti-
inflammatory potential by inhibition of iNOS COX-2, and cytokines via NF-kB pathway.
J Hepatol ., 38(3): 289–97.
Kim, D. Lee, E.S. Oh, K.T. Gao, Z.G. Bae, Y.H. 2008. Doxorubicin-loaded polymeric micelle
overcomes multidrug resistance of cancer by double-targeting folate receptor and early
endosomal pH. Small., 4: 2043–2050.
Kim, R. Tanabe, K. Uchida, Y. Emi, M. Inoue, H. Toge, T. 2002. Current status of the molecular
mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level
analysis to cancer chemotherapy. Cancer Chemotheraphy and Pharmacology., 50: 343–
352.
Bibliography Kim, S.W. Han, Y.W. Lee, S.T. Jeong, H.J. Kim, S.H. Kim, I.H.l. 2008. A superoxide anion
generator, pyrogallol, inhibits the growth of HeLa cells via cell cycle arrest and
apoptosis. Mol Carcinogen., 47: 114-25.
Kinnane, C.R. Such, G.K. Antequera-Ga rcía, G. Yan, Y. Dodds, S.J. Liz-Marzan, L.M.
Caruso, F. 2009. Low-fouling poly(N-vinyl pyrrolidone) capsules with engineered de-
gradable properties. Biom acromolecules ., 10 : 2839 – 2846.
Kirkin, V. Joos, S. Zornig. M. 2004. The role of Bcl-2 family members in tumorigenesis.
Biochim Biophys Acta., 1644: 229-249.
Kisak, E.T. Coldren, B. Evans, C.A. Boyer, C. Zasadzinski, J.A. 2004. The vesosome-a
multicompartment drug delivery vehicle. Curr. Med. Chem., 11:199-219.
Kleihues, P. Ohgaki, H. 2000. Phenotype vs genotype in the evolution of astrocytic brain
tumors. Toxicol Pathol., 28:164-170.
Kleihues, P. Louis, D.N. Scheithauer, B.W. Rorke, L.B. Eifenberger, G. Burger, P.C.
Cavenee, W.K. 2002. The WHO classification of tumors of the nervous system. J.
Neuropathol. Exp. Neurol., 61: 215-225.
Kobayashi, T. Ishida, T. Okada, Y. Ise, S. Harashima, H. Kiwada, H. 2007. Effect of
transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug
resistant tumor cells. Int. J. Pharm., 329 (1-2): 94-102.
Kockisch, S. Rees, G.D. Young, S.A. Tsibouklis, J. Smart, J.D. 2005. Mucoadhesive, triclosan-
loaded polymer microspheres for application to the oral cavity: preparation and
controlled release characteristics. Eur. J. Pharm. Biopharm., 59: 207-216.
Bibliography Konecny, G. Pauletti, G. Pegram, M. Untch, M. Dandekar, S. Aguilar, Z. 2003. Quantitative
association between HER-2/neu and steroid hormone receptors in hormone receptor-
positive primary breast cancer. J. Natl. Cancer Inst., 95:142–153.
Koppler, M. Taubert, H. Bertel, F. Blumke, K. Panjan, M. Schmidt, H. Bache, M. 2005. Radio
sensitization, after a combined treatment of survivin by siRNA and irradiation is
correlated of pancreatic cancer caspase 3 and 7 in a wt-p53 sarcoma cell line, but not in a
mt-p53 sarcoma cell line. Oncol Rep., 13: 167-172.
Kowshik, M. Vogel, W. Urban, J. Kulkarni, S.K. Paknikar, K.M. 2002. Microbial synthesis of
semiconductor PbS nano-crystallites. Adv Mater., 14: 815–818.
Kumar, N. 1981. Taxol-induced polymerization of purified tubulin. Mech-anism of action. J.
Biol. Chem., 256: 10435–10441.
Kumar, S. Harrison, N. Richards-Kortum, R. Sokolov, K. 2007. Plasmonic nanosensors for
imaging intracellular biomarkers in live cells. Nano Lett., 7: 1338–1343.
Kumar, V. Green, S. Stack, G. Berry, M. Jin, J.R. Chambon, P. 1987. Functional domains of
the human estrogen receptor. Cell., 51: 941–951.
Kumar, V. Green, V.S. Staub, A. Chambon, P. 1986. Localisation of the oestradiol-binding and
putative DNA-binding domains of the human oestrogen receptor. EMBO J., 5: 2231-
2236.
Lampson, M.A. Renduchitala, K. Khodhakuv, A. Kapoor, T.M. 2004. Correcting improper
chromosome-spindle attachment during cell division. Nat Cell Biology., 798-812.
Lee, E.S. Gao, Z.G. Kim, D. Park, K. Kwon, I.C. Bae, Y.H. 2008. Super pH-sensitive
multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug
resistance. J. Control. Release., 129: 228–236.
Bibliography Lee, M.K. Chun, S.K. Choi, W.J. Kim, J.K. Choi, S.H. Kim, A. Oungbho, K. Park, J.S. Ahn,
W.S. Kim, S.K. 2005. The use of chitosan as a condensing agent to enhance emulsion-
mediated gene transfer. Biomaterials., 26: 2147-2156.
Levin E.R. 2009. Plasma membrane estrogen receptors. Trends in Endocrinology and
Metabolism ., 20 (10): 477-482.
Li and Xiang Ling. 2006. Survivin study: An update of “What is the Next Wave”. J.Cell.
Physiol., 208: 476-86.
Li F. 2003.Survivin study: what is the next wave? J Cell Physiol.,1971: 8–29.
Liebmann, J. Cook, J.A. Mitchell, J.B. Cremophor, E.L. 1993. Solvent for paclitaxel, and
toxicity. Lancet., 342: 1428.
Liu, T. Brouha, B. Grossman, D. 2004. Rapid induction of mitochondrial events and caspase-
independent apoptosis in survivin targeted melanoma cells. Oncogene., 23: 39-48.
Logue, S.E. Martin, S.J. 2008. Caspase activation cascades in apoptosis. Biochem Soc Trans.,
36: 1-9.
Loo, C. Lowery,A. Halas, N. West, J. Drezek, R. 2005. Immunotargeted nanoshells for
integrated cancer imaging and therapy. Nano Lett., 5: 709–711.
Lopergolo, L.C. Lugao, A.B. Catalani, L.H. 2003. Direct UV photocrosslinking of poly (N-
vinyl-2-pyrrolidone) (PVP) to produce hydrogels. Polymer .,44: 6217-6222.
Lu, D. Wientjes, M.G. Lu, Z. Au, J.L. 2007. Tumor priming enhances delivery and efficacy of
nanomedicines. J Pharmacol Exp Ther., 322: 80–88.
Lukyanov, A.N . Torchilin, V.P. 2004. Micelles from lipid derivatives of water-soluble polymers
as delivery systems for poorly soluble drugs. Adv. Drug Deliv. Rev., 56 (9): 1273-1289.
Bibliography Luo, L.B. Ranger, M. Lessard, D.G. Le Garrec, D. Gori, S. Leroux, J.C. Rimmer, S. Smith, D.
2004. Novel amphiphilic diblock copolymer of low molecular weight poly(N-
vinylpyrrolidone)-block-poly(D, L-lactide): synthesis, characterization, and micellization.
Macromolecules., 37 (11) : 4008–4013.
Ly, J.D. Grubb, D.R. Lawen, A. 2003. The mitochondrial membrane potential (deltapsi(m)) in
apoptosis; an update. Apoptosis., 8: 115–128.
Maeda, H. Fang, J. Inutsuka, T. Kitamoto, Y. 2003. Vascular permeability enhancement in solid
tumor: various factors, mechanisms involved and its implications. Int.
Immunopharmacol., 3: 319–328.
Maeda, H. Seymore, L.W. Miyamoto, Y. 1992. Conjugates of anticancer agents and polymers:
advantages of macromolecular therapeutics in vivo. Bioconjugate Chemistry., 3: 351-
162.
Mao, S. Sun, W. Kissel, T. 2010. Chitosan-based formulations for delivery of DNA and siRNA.
Advanced Drug Delivery Reviews., 62:12-27.
Marambio-Jones, C. Hoek, E.M.V. 2010. The antibacterial effects of silver nanomaterials and
potential implications for human health and the environment. J Nanopart Res., 12:1531–
1551.
Missirlis, D. 2005. Amphiphilic hydrogel nanoparticles. Preparation, characterization, and
preliminary assessment as new colloidal drug carriers. Langmuir., 21: 2605–2613.
Miura, N. Shinohara, Y. 2009. Cytotoxic effect and apoptosis induction by silver nanoparticles in
HeLa cells. Biochemical and Biophysical Research Communications .,390: 733-737.
Bibliography Mo, Y. Lim, L.Y. 2005. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer
activity by surface conjugation with wheat germ agglutinin. J Control Release., 108:
244–62.
Mo, Y. Lim, L.Y. 2005. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer
activity by surface conjugation with wheat germ agglutinin. J Control Release., 108:
244-262.
Mohamed, T. El-Ghamry. Roland, W.F. 1968. Spectrophotometric Determination of Trace
Amounts of Silver. Anal Chem., 40: 1986-1990.
Mu, L. Feng, S.S. 2003. A novel controlled release formulation for the anticancer drug Paclitaxel
(Taxol): PLGA nanoparticles containing vitamin E. TPGS, J. Control. Release., 86: 33–
48.
Naik, R.R. Stringer, S.J. Agarwal, G. Jones, S.E. Stone, M.O. 2002. Biomimetic synthesis and
patterning of silver nanoparticles. Nat Mater., 1: 169-72.
Narayanan, K.B. Sakthivel, N. 2010. Biological synthesis of metal nanoparticles by microbes.
Adv Colloid Interface Sci., 156:1–13.
Naugler, W.E. Karin, M. 2008. NF-kappaB and cancer- identifying targets and mechanisms.
Curr Opin Genet Dev., 18: 19-26.
Nel, A. E. Madler, L. Velegol, D. Xia, T. Hoek, E. M. Somasundaran, P. Klaessig, F.
Castranova, V. Thompson, M. 2009. Understanding Biophysicochemical Interactions at
the Nano-Bio Interface. Nat. Mater., 8: 543–557.
Ni, C.D. Ma, Y.D. 2006. Immunohistochemistry experiment technology and application.
Chemical Industry Publishing Company, Beijing., 86.
Bibliography Nicolis, E. Lampronti, I. Dechecchi, M.C. Borgatti, M. Tamanini, A. Bianchi, N. Bezzerri, V.
Mancini, I. Giri, M.G. Rizzotti, P. Gambari, R. Cabrini, G. 2008. Pyrogallol, an active
compound from the medicinal plant Emblica of ficinalis, regulates expression of
proinflammatory genes in bronchial epithelial cells. International
Immunopharmacology., 8: 1672-1680.
Nihal, M. Ahmad, N. Mukhtar, H. Wood, G.S. 2005. Anti-proliferative and proapoptotic effects
of ()-epigallocatechin-3-gallate on human melanoma: possible implications for the
chemoprevention of melanoma. International Journal of Cancer., 114: 513–521.
Ntalli, N.G. Cottiglia, F. Bueno, C.A. Alche, L.E. Leonti, M. Vargiu, S. 2010. Cytotoxic
Tirucallane Triterpenoids from Melia azedarach fruits. Molecules., 15: 5866-5877.
Nyman, D.W. Campbell, K.J. Hersh, E. Long, K. Richardson, K. Trieu. V. et al., 2005. Phase I
and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in
patients with advanced nonhematologic malignancies. J. Clin. Oncol., 23: 7785–7793.
O’Connor, D.S. Schechner, J.S. Adida, C. 2000. Control of apoptosis during angiogenesis by
survivin expression in endothelial cells. Am J Pathol., 1562: 393–398.
O’Regan, R.M. Jordan, V.C. 2002. The evolution of tamoxifen therapy in breast cancer: selective
oestrogen-receptor modulators and downregulators. Lancet Oncol., 3: 207–214.
Ohno, Y. Fukuda, K. Takemura, G. Toyota, M. Watanabe, M. Yasuda, N. 1999. Induction of
apoptosis by gallic acid in lung cancer cells. Anticancer Drugs., 10: 845-851.
Oltvai, Z.N. Milliman, C.L. Korsmeyer, S.J. 1993. Bcl-2 heterodimerizes in vivo with a
conserved homolog, Bax, that accelerates programmed cell death. Cell., 74: 609–619.
Osborne, C.K. 1998. Drug therapy-Tamoxifen in the treatment of breast cancer. N Engl J Med.,
339:1609-1618.
Bibliography Paleos, C.M. Tsiourvas, D. Sideratou, Z. Tziveleka, L. Acid- and salt-triggered multifunctional
poly(propylene imine) dendrimer as a prospective drug delivery system,
Biomacromolecules ., 5 : 524-529.
Pan, B. Cui, D. Sheng,Y. Ozkan, C. Gao, F. He, R. et al., 2007. Dendrimer-Modified Magnetic
anoparticles Enhance Efficiency of Gene Delivery System Cancer. Res., 67: 8156–8163.
Paoluzzi, L. O’Connor, O.A. 2010. Targeting survival pathways in lymphoma. Adv. Exp. Med.
Biol., 687: 79–96.
Park, W.H. Han, Y.W. Kim, S.H. Kim, S.Z. 2007. A superoxide anion generator, Pyrogallol
induces apoptosis in As4.1 cells through the depletion of intracellular GSH content.
Mutat Res., 619: 81-92.
Parkin, D.M. 2001. Global cancer statistics in the year 2000. Lancet Oncol., 2: 533–543.
Parveen, S. Sahoo, S.K. 2008. Polymeric nanoparticles for cancer therapy. J. Drug Target., 16:
108–123.
Pedram, A. Razandi, M. Levin, E.R. 2006. Nature of functional estrogen receptors at the plasma
membrane. Mol. Endocrinol., 20 (9): 1996–2009.
Peng, J. He, X. Wang, K. Tan, W. Li, H. Xing, X. 2006. An antisense oligonucleotide carrier
based on amino silica nanoparticles for antisense inhibition of cancer cells.
Nanomedicine., 2:113–120.
Pennati, M. Folini. M. Zaffaroni, N. 2007. Targeting survivin in cancer therapy: fulfilled
promises and open questions. Carcinogenesis., 286:1133–1139.
Pinhassi, R.I. Assaraf, Y.G. Farber, S. Stark, M. Ickowicz, D. Drori, S. Domb, A.J. Livney, Y.D.
2010. Arabinogalactan-folate-drug conjugate for targeted delivery and target-activated
Bibliography
release of anticancer drugs to folate receptor-overexpressing cells. Biomacromolecules.,
11: 294–303.
Pound, G. McKenzie, J.M. Lange, R.F.M. Klumperman, B. 2008. Polymer–protein conjugates
from aldehyde endfunctional poly (N-vinylpyrrolidone) synthesised via xanthate-
mediated living radical polymerization. Chem. Commun., 27: 3193 –3195.
Qi, F. Li, A. Zhao, L. Xu, H. Inagaki, Y. Wang, D. 2010. Cinobufacini, an aqueous extract from
Bufobufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated
pathway in human hepato cellular carcinoma cells. J Ethnopharmacol., 128: 654-661.
Qiao, L. Wong, B.C. 2009. Targeting apoptosis as an approach for gastrointestinal cancer
therapy. Drug Resist. Update., 12: 55-64.
Radhika, N.K. Sreejith, P.S. Asha, V.V. 2010. Cytotoxic and apoptotic activity of Cheilanthes
farinose (Forsk.) Kaulf. Against human hepatoma, Hep3B cells. J Ethnopharmacol.,
128: 166-171.
Rajkapoor, B. Sankari, M. Sumithra, M. Anbu, J. Harikirishnan, N. Gobinath, M. 2007.
Antitumor and cytotoxic effects of Phyllanthus polyphyllus on ehrlich ascites carcinoma
and human cancer cell lines. Biosci Biotechnol Biochem., 71(9): 2177–2183.
Rao, G.S. 1981. Mode of entry of steroid and thyroid hormones into cells. Mol. Cell.
Endocrinol., 21: 97–108.
Ravdin, P.M. Green, S. Dorr, T.M. McGuire, W.L. Fabian, C. Pugh, R.P. 1992. Prognostic-
significance of progesterone-receptor levels in estrogen receptor-positive patients with
metastatic breast-cancer treated with tamoxifen-results of a prospective Southwest-
Oncology-Group Study. J Clin Oncol., 10:1284–91.
Bibliography Raveendran, P. Fu, J. Wallen, S.L. 2003. Completely "green" synthesis and stabilization of metal
nanoparticles. J Am Chem Soc.,125 (46):13940-13951.
Raymond, E. Faivre, S. Chaney, S. Woynarowski, J.M. 2002. Cellular and molecular
pharmacology of Oxaliplatin. Mol Cancer Ther., 1 : 227–235.
Reed, J.C. 2003. Apoptosis-targeted therapies for cancer. Cancer Cell., 3: 17.
Reents, R. Jeyaraj, D.A. Waldmann, H. R. 2002. Enzymatically cleavable linker groups in
polymer-supported synthesis. Drug Discov., Today 7: 71-76.
Reiko, H. Ronan, K. Erich, A.N. 2003. Exploring the functional interaction between Aurora B,
INCEP and survivin in mitosis. Mol. Cell. Biol., 23: 3325-3341.
Resnick, T. D. 2006. INCEP and Aurora B promote in meiotic sister chromatid cohesion through
localization of the shugoshin ME1-S332 drosophila. Dev.Cell., 11: 57-68.
Rivera, E. 2003. Liposomal anthracyclines in metastatic breast cancer: clinical update
Oncologist 8: 3-9.
Robey, R.W. Shukla, S. Finley, E.M. Oldham, R.K. 2008. Inhibition of P-glycoprotein
(ABCB1)- and multidrug resistance-associated protein 1(ABCC1)-mediated transport by
the orally administered inhibitor, CBT-1®. Biochem. Pharmacol., 75: 1302–1312.
Robidoux, A. Buzdar, A.U. Quinaux, E. Jacobs, S. Rastogi, P. 2010. A phase II neo adjuvant
trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-
fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer. Clin. Breast
Cancer., 10: 81-86.
Rosa, J. Canovas, P. Islam, A. Altieri, D.C. Doxsey, S.J. 2006. Survivin modulates
microtubule dynamics and nucleation throughout the cell cycle. Mol. Biol. Cell., 17:
1483–1493.
Bibliography Rouf, M.A. Vural, I. Renoir, J.M. Hincal, A.A. 2009. Development and characterization of
liposomal formulations for rapamycin delivery and investigation of their antiproliferative
effect on MCF7 cells. J. Liposome Res., 19: 322–331.
Ruchaud, S. Carmena, M. Earnshaw, W.C. 2007. Chromosomal passengers: conducting cell
division. Nat. Rev. Mol. Cell Biol., 8: 798–812.
Rudolph, C. Plank, C. Lausier, J. Schillinger, U. Müller, R.H. Rosenecker, J. 2003. Oligomers of
the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid
DNA into cells. J. Biol. Chem., 278: 11411–11418.
Ryan, B.M, Norma, O’Donovan, Michael, J. Duffy. 2009. Survivin: A new target for anti-cancer
therapy. Cancer Treatment Reviews 35: 553-562.
Saeki, K. Hayakawa, S. Isemura, M. Miyase, T. 2000. Importance of a pyrogallol-type structure
in catechin compounds for apoptosis-inducing activity. Phytochemistry., 53: 391-394.
Salem, A.K. Searson, P.C. Leong, K.W. 2003. Multifunctional nanorods for gene delivery, Nat.
Mater., 2: 668-671.
Sampath, S.C. Ohi, R. Leismann, O. Salic, A. Pozniakovski, A. Funabiki, H. 2004. The
chromosomal passenger complex is required for chromatin-induced microtubule
stabilization and spindle assembly. Cell., 118 :187-202.
Sanchez-Lamaz, A. Fiore, M. Cundari, E. Rocordy, R. Cozzi, R. De Salvia, R. 1999. Phyllanthus
orbicularis aqueous extracts: cytotoxic, genotoxic, and antimutagenic effects in the CHO
cell line. Toxicol Appl Pharmacol., 161: 231-239.
Sandall, S. Severin, F. McLeod, I.X. Yates, J.R. Oegema, K. Hyman, A. Desai, A. 2006. A
Bir1–Sli15 complex connects centromeres to microtubules and is required to sense
kinetochore tension. Cell., 127: 1179-1191.
Bibliography Sanhai, W.R. Sakamoto, J.H. Canady, R. Ferrari, M. 2008. Seven challenges for nanomedicine.
Nat. Nanotechnol., 3: 242–244.
Sathishkumar, M. Sneha, K. Won, S.W. Cho, C.W. Kim, S. Yun, Y.S. 2009. Cinnamon
zeylanicum bark extract and powder mediated green synthesis of nanocrystalline silver
particles and its bactericidal activity. Colloids Surf. B: Bioint., 73: 332-338.
Schleicher, S.M., Moretti, L., Varki, V., Lu, B. 2010. Progress in the unraveling of the
endoplasmic reticulum stress/autophagy pathway and cancer: implications for future
therapeutic approaches. Drug Resist. Update., 13, 79–86.
Schoenmakers, R.G. 2004. The effect of the linker on the hydrolysis rate of drug-linked ester
bonds. J. Control. Release., 95:291-300.
Schultz, D.R. Harrington, W.J. 2003. Apoptosis: programmed cell death at a molecular level
Semin. Arthritis Rheum., 32: 345-369.
Sengupta, S. Eavarone, D. Capila, I. Zhao, G.L. Watson, N. Kiziltepe, T. 2005. Temporal
targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature.
436: 568-572.
Sengupta, S. Tyagi, P. Velpandian, T. Gupta, Y.K. Gupta, S.K. 2000. Etoposide encapsulated in
positively charged liposomes: pharmacokinetic studies in mice and formulation stability
studies. Pharmacol Res., 424: 59-64.
Sethi, G. Sung, B. Aggarwal, B.B. 2008. Nuclear factor-kappaB activation: from bench to
bedside. Exp Biol Med., 233: 21-31.
Sha, N. K. Khan, G. J. Bisen, P. S. 2006. Structural, functional and therapeutic biology of
survivin. Cancer Letters., 244:164-171.
Bibliography Shafi, G. Munshi, A. Hasan, T.N. 2009. Induction of apoptosis in HeLa cells by chloroform
fraction of seed extracts of Nigella sativa. Cancer Cell Int., 9: 29.
Shenoy, D.B. Amiji, M.M. 2005. Poly (ethyleneoxide)-modified poly (epsilon-caprolactone)
nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm., 293: 261-
270.
Shi, Y. 2002. Mechanisms of caspase activation and inhibition during apoptosis. Molecular
Cell., 9: 459-470.
Shi, Y.A. 2001. A structural view of mitochondria-mediated apoptosis. Nat. Struct. Biol., 8:
394-401.
Singh, M. Singh, O. Talwar, G.P. 1995. Biodegradable delivery system for a birth control
vaccine: immunogenicity studies in rats and monkeys. Pharm Res., 12(11):1796-800.
Slamon, D.J. Clark, G.M. Wong, S.G. Levin, W.J. Ullrich, A. McGuire, W.L. 1987. Human
breast cancer: correlation of relapse and survival with amplification of the HER-2/neu
oncogene. Science., 235: 177–182 .
Slamon, D.J. Godolphin, W. Jones, L.A. Holt, J.A. Wong, S.G. Keith, D.E. 1989. Studies of
the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science., 244: 707–
712.
Slamon, D.J. Leyland-Jones, B. Shak, S. Fuchs, H. Paton, V. Bajamonde, A. 2001. Use of
chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that
over-expresses HER2 N. Engl. J. Med., 344: 783–792 .
Snyder, E.L. Saenz, C.C. Denicourt, C. Meade, B.R. Cui, X.S. Kaplan. I. M. 2005. Enhanced
targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by
transducible anticancer peptides. Cancer Res., 65: 10646–10650.
Bibliography Song, M. Wang, X.M. Li, J.Y. Zhang, R.Y. Chen, B.A. Fu, D.G. 2008. Effect of surface
chemistry modification of functional gold nanoparticles on the drug accumulation of
cancer cells. J. Biomed. Mater. Res., 86: 942-946.
Song,M. Guo, D.D. Pan, C. Jiang, H. Chen, C. Zhang, R.Y. Gu, Z.Z. Wang, X.M. 2008. The
application of poly (N-isopropylacrylamide)-co-polystyrene nanofibers as an additive
agent to facilitate the cellular uptake of an anticancer drug. Nanotechnology.,19.
Sood, P. Thurmond, K.B. Jacob, J.E. Waller, L.K. Silva, G.O. Stewart, D,R. Nowotnik, D.P.
2006. Synthesis and characterization of AP5346, a novel polymer-linked
diaminocyclohexyl platinum chemotherapeutic agent. Bioconjug Chem., 171: 270–279.
Sreekumaran, A.N. Tom, R.T. Rajeev Kumar, V.R. Subramaniam, C. Pradeep, T. 2007.
Chemical interactions at noble metal nanoparticle surfaces-catalysis, sensors and devices.
Cosmos., 3: 103-124.
Steinhauser, I. Spankuch, B Strebhardt, K. Langer, K. 2006. Trastuzumab-modified
nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials., 27:
4975–4983.
Sukirtha, R. Priyanka, K. Antony, J.J. Kamalakkannan, S. Thangam, R. Gunasekaran, P.
Krishnan, M. Achiraman, S. 2012. Cytotoxic effect of Green synthesized silver
nanoparticles using Melia azedarach against in vitro HeLa cell lines and lymphoma mice
model. Pro Biochem., 47: 273-279.
Sun, L. Wang, L. Yonghai Song. Guo, C. Sun, Y. Peng, C. 2008. Aggregation-based growth of
silver nanowires at room temperature. App Surf Sci., 254: 2581-2587.
Bibliography Susa, M. Iyer, A.K. Ryu, K. Hornicek, F.J. Mankin, H. Amiji, M.M. Duan, Z.F. 2009.
Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug
resistance in osteosarcoma. BMC Cancer., 9: 399.
Susanne, M.A. Lens, Gerben Vader and Rene, H. Medema. 2006. The case of survivin as mitotic
regulator. Current openion in Cell Biology, 18: 616-622.
Suzuki, A. Ito, T. Hayashida, M. 2000. Survivin initiates procaspase3/p21 complex formation as
a result of interaction with Cdk4 to resist Fas-mediated cell death. Oncogene., 19 : 1346-
1353.
Szakacs, G. Paterson, J.K. Ludwig, J.A. Booth-Genthe, C. Gottesman, M.M. 2006. Targeting
multidrug resistance in cancer. Nat. Rev. Drug Discov., 5: 219-234.
Takakura, Y. Hashida, M. 1995. Macromolecular drug carrier systems in cancer che-motherapy:
macromolecular prodrugs. Critical Reviews in Oncology/Hema-tology., 18: 207–31.
Tasciotti, E. Liu, X.W. Bhavane, R. Plant, K. Leonard, A.D. Price, B.K. 2008. Mesoporous
silicon particles as a multistage delivery system for imaging and therapeutic applications.
Nat. Nano-technol., 3: 151–157.
Thei, T. Peter, D. Eric Drexler, J.K. 2006. Nanotechnology. Nat. Nanotechnol., 1:8–10.
Todd, R.C. Lippard, S.J. 2009. Inhibition of transcription by platinum antitumor compounds.
Metallomics 1(4):280-291.
Torresdey, J.L. Parsons, J.G. Gomez, E. Videa, J.P. Troiani, H.E. Santiago, P. 2002. Formation
and growth of Au nanoparticles inside live Alfalfa plants. Nano Lett., 2: 397-401.
Tripathy, A. Raichur, A.M. Chandrasekaran, N. Prathna, T.C. Mukherjee, A. 2010. Process
variables in biomimetic synthesis of silver nanoparticles by aqueous extract of
Azadirachta indica (Neem) leave. J Nanopart Res., 12: 237-246.
Bibliography Tsuda, H. Ohshima, Y. Nomoto, H. 2004. Cancer prevention by natural compounds. Drug
Metab Pharmacokinet .,19: 245-263.
Umesono, K. Evans, R.M. 1989. Determinants of target gene specificity for steroid/thyroid
hormone receptors. Cell., 57: 1139–1146.
Uren, A.G. 2000. Survivin and the INCENP show similar cell-cycle localization and gene
knockout phenotype. Curr. Biology., 10: 1319-1328.
Vader, G. Kauw, J.J. Medema, R.H. Lens, S.M. 2006. Survivin mediates targeting of the
chromosomal passenger complex to the centromer and midbody. EMBO Rep., 7: 85-92.
Vagnarelli, P. Earnshaw, W.C. 2004. Chromosomal passenger: the four dimensional regulation
of mitotic events. Chromosoma., 113: 211-222.
Verma, A. Stellacci, F. 2010. Effect of Surface Properties on Nanoparticle-Cell Interactions.
Small., 6:12-22.
Verrijk, R. Smolders, I.J. Bosnie, N. Begg, A.C. 1992. Reduction of systemic exposure and
toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide. Cancer Res., 52:
6653–6656.
Vigneshwaran, N. Kathe, A.A. Varadarajan, P.V. 2007. Nachane RP, Balasubramanya RH.
Functional finishing of cotton fabrics using silver nanoparticles. J. Nanosci
Nanotechnol., 7:1893-1897.
Von Hoff, D.D. Layard, M.W. Basa, P. Davis Jr, H.L. Von Hoff, A.L. Rozencweig, M. 1979.
Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med., 9: 710–
717.
Vong, Q. P. Cao, K. Li, H. Y. Lglesia, P. A. Zheng. Y. 2005. Chromosome alignment and
segregation regulated by ubiquitination of survivin. Science., 310: 1499-1504.
Bibliography Wang D, Lippard S.J. 2005. Cellular processing of platinum anticancer drugs. Nat. Rev. Drug.
Discov., 2005: 4: 307-320.
Wang, Z. Fukunda, S. Pelus, L.M. 2004. Survivin regulates the p53 tumor suppressor gene
family. Oncogene., 23: 8146-8153.
Wenzel, U. Kuntz, S. Brendel, M.D. Daniel, H. 2000. Dietary flavone is a potent apoptosis
inducer in human colon carcinoma cells. Cancer Research., 60: 3823-3831.
Whealey, S. Carvalho, P. Vagnarelli, P. Earnshaw, W. 2001. INCEP is required for proper
targeting of survivin to the centromeres and proper anaphase spindle during mitosis. Curr
Bio., 11: 886-890.
Wheatly, P. Meneish, A. 2005. Survivin: A protein with dual role in mitosis and apoptosis.
International Review of cytology: 247.
Wimmershioff, J. Polkinghorne, A. Grest, P. Schade, B. Marchal, T. Keller, S.M. Guscetti, F.
2010. Immunohistochemical detection of survivin in canine lymphoma. J. Comp. Path.,
1-12.
Wu, J. Akaike, T. Hayashida, K. Okamoto, T. Okuyama, A. Maeda, H. 2001. Enhanced
vascular permeability in solid tumor involving peroxynitrite and matrix metallo
proteinases. Jpn. J. Cancer Res., 92: 439–451.
Wu, W. Wieckowski, S. Pastorin, G. Benincasa, M. Klumpp, C. Briand, J.P. Gennaro, R.
Prato, M. Bianco, A. 2005. Targeted delivery of amphotericin B to cells by using
functionalized carbon nanotubes. Angew. Chem., Int. Ed., 44: 6358-6362.
Xia, W. Low, P.S. 2010. Folate-targeted therapies for cancer. J. Med. Chem., 53: 6811–6824.
Bibliography Xu, J. Ma, L. Liu, Y. Xu, F. Nie, J. Ma, G. 2012. Design and characterization of antitumor
drug paclitaxel-loaded chitosan nanoparticles by W/O emulsions. Int J Biol Macromol.,
50 : 438-443.
Xu, P.S. Van Kirk, E.A. Zhan, Y.H. Murdoch, W.J. Radosz, M. Shen, Y.Q. 2007. Targeted
charge-reversal nanoparticles for nuclear drug delivery. Angew. Chem., Int. Ed., 46:
4999-5002.
Xu, X.Y. Yang, Q.B. Bai, J. Lu, T.C. Li, Y.X. Jing, X.B. 2008. Fabrication of biodegradable
electrospun poly(L-lactide-co-glycolide) fibers with antimicrobial nanosilver particles. J
Nanosci Nanotechnol., 8: 5066-5070.
Xu, Y.M. Du, Y.M. 2003. Effect of molecular structure of chitosan on protein delivery properties
of chitosan nanoparticles. Int J Pharm .,250: 215-226.
Yan, F. Xu, H. Anker, J. Kopelman, R. Ross, B. Rehemtulla, A. 2004. Synthesis and
characterization of silica-embedded iron oxide nanoparticles for magnetic resonance
imaging. J. Nanosci. Nano-technol., 4: 72–76.
Yang, C.J. Wang, C.S. Hung, J.Y. Huang, H.W. Chia, Y.C. Weng, P.C. Huang, M.S. 2009.
Pyrogallol induces G2-M arrest in human lung cancer cells and inhibits tumor growth in
an animal model. Lung Cancer., 66: 162–168.
Yang, X. Wang, H. Beasley, D.W. Volk, D.E. Zhao, X. Luxon B.A. 2006. Selection of
thioaptamers for diagnostics and therapeutics. Ann. N. Y. Acad. Sci., 1082:116-119.
Yang, X. 2000. Transcriptional activation of estrogen receptor alpha in human breast cancer cells
by histone deacetylase inhibition. Cancer Res., 60: 6890–6894.
Yarden, Y. Sliwkowski, M.X. 2001. Untangling the ErbB signalling network. Nat. Rev. Mol.
Cell Biol., 2: 127–137.
Bibliography Yezhelyev, M.V. Gao, X. Xing, Y. Hajj, A.A. Nie, S. O’Regan, R.M. 2006. Emerging use of
nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol., 7: 657-667.
Yin, B. Ma, H. Wang, S. Chen, S. 2003. Electrochemical synthesis of silver nanoparticles under
protection of poly(N-vinylpyrrolidone). J Phys Chem B., 107: 8898-904.
Yong, K.T. Qian, J. Roy, I. Lee, H.H. Bergey, E.J. Tramposch K.M. 2007. Quantum rod
bioconjugates as targeted probes for Confocal and two-photon fluorescence imaging of
cancer cells. Nano Lett., 7: 761–765.
Youle, R.J. Strasser, A. 2008. The BCL-2 protein family: opposing activities that mediate cell
death. Nat.Rev.Mol Cell Biol., 9: 47-59.
Yu, S.W. Wang, H. Dawson, T.M. Dawson, V.L. 2003. Poly (ADP-ribose) polymerase-1 and
apoptosis inducing factor in neurotoxicity. Neurobiology of Disease., 14: 303-317.
Yuan, F. Dellian, M. Fukumura, D. Leunig, M. Berk, D.A. Torchilin, V.P. Jain, R.K. 1995.
Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff
size. Cancer Res., 553:752–756.
Zaffaroni, N. Pennati, M. Colella, G. 2002. Expression of the anti-apoptotic gene survivin
correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci., 59: 1406-
1412.
Zeiger, E.1998. Pyrogallol-review of toxicological literature. North Carolina: National Institute
of Environmental Health Sciences., 87: 66-71.
Zhang, M. Mukherjee, N. Bermudez, R.S. 2005. Adenovirus-mediated inhibition of survivin
expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
Prostate: 64: 293-302.
Bibliography Zhang, Y.J. Nagao, T. Tanaka, T. Yang, C.R. Okabe, H. Kouno, I. 2004. Antiproliferative
activity of the main constituents from Phyllanthus emblica. Biol Pharm Bull.,
27(2):251–255.
Zhu, Z. Yuan, Li. Xiaolin Li. Rutian Li. Zhijun Jia. Baorui Liu. Wanhua Guo. Wei Wu. Xiqun
Jiang. 2010. Paclitaxel-loaded poly( N-vinylpyrrolidone)- b-poly(ε-caprolactone)
nanoparticles: Preparation and antitumor activity in vivo. Journal of Controlled
Release., 142 : 438-446.